When was 2seventy bio founded?

2seventy bio was founded in 2021.

Where is 2seventy bio located?

2seventy bio is headquartered in Cambridge, United States.

How many employees does 2seventy bio have?

As of Apr 30, 2026, the latest employee count at 2seventy bio is 63.

Is 2seventy bio a funded company?

2seventy bio is a funded company, having raised a total of $***** in its 1st and only funding round.

How much is 2seventy bio worth?

The last known valuation of 2seventy bio was $***** as of Mar 11, 2025.

What is the annual revenue of 2seventy bio?

Annual revenue of 2seventy bio is between $10M and $50M as on Dec 31, 2024

Where does 2seventy bio rank among its competitors?

2seventy bio ranks 869th amongst 3313 active competitors, of which 1145 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of 2seventy bio?

2seventy bio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

2seventy bio - 2026 Company Profile, Team, Competitors & Financials

Company Details

Developer of cellular therapies for the treatment of cancer. The company uses multiple engineered cell therapies that combine lentiviral vector, CAR-T, and TCR technologies to address the challenge of tumor control and elimination. The company's flagship product is Abecma for multiple myeloma and focuses on the development of therapies for a broad range of hematologic malignancies.

Website: 2seventybio.com
Social
Email ID: *****@2seventybio.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2021

Location

Cambridge, United States

Stage

Acquired

Last Known Valuation

$***** as on Mar 11, 2025

Ranked

869^th among 3313 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2024

Employee Count

63 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3124 more

Exit Details

Acquired by Bristol-Myers Squibb (Mar 11, 2025)

View 2seventy bio's full profile

2seventy bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
2SEVENTY BIO, INC. CIN: 1860782 , United States, Active	Apr 25, 2021	$10M - $50M (As on Dec 31, 2024)	416 (As on Dec 31, 2021)	-

2seventy bio got acquired by Bristol-Myers Squibb on Mar 11, 2025 at an acquisition amount of $*****.

Click here to take a look at 2seventy bio's acquisition in detail

2seventy bio has not raised any funding rounds yet.

2seventy bio's employee count trend

2seventy bio has 63 employees as of Apr 26. Here is 2seventy bio's employee count trend over the years:

Uncover 2seventy bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 2seventy bio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of 2seventy bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	Khosla Ventures, True North & 23 others	71/100
869th	2seventy bio 2021, Cambridge (United States), Acquired	Developer of cellular therapies for the treatment of cancer	-	-	45/100